NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$76.01 +0.36 (+0.48 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$75.65
Today's Range$73.99 - $76.60
52-Week Range$45.05 - $84.20
Volume500,500 shs
Average Volume246,307 shs
Market Capitalization$1.10 billion
P/E Ratio22.55
Dividend YieldN/A
Beta1.47
Eagle Pharmaceuticals logoEagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300

Debt

Debt-to-Equity Ratio0.23
Current Ratio5.87
Quick Ratio5.66

Price-To-Earnings

Trailing P/E Ratio22.55
Forward P/E Ratio39.59
P/E GrowthN/A

Sales & Book Value

Annual Sales$236.71 million
Price / Sales4.77
Cash Flow$3.9404 per share
Price / Cash19.29
Book Value$12.01 per share
Price / Book6.33

Profitability

EPS (Most Recent Fiscal Year)$3.37
Net Income$51.94 million
Net Margins15.32%
Return on Equity21.89%
Return on Assets15.09%

Miscellaneous

Employees108
Outstanding Shares14,840,000

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How will Eagle Pharmaceuticals' stock buyback program work?

Eagle Pharmaceuticals announced that its Board of Directors has authorized a stock buyback program on Thursday, August 10th 2017, which authorizes the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 13.3% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) released its quarterly earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported $0.53 EPS for the quarter, missing the Zacks' consensus estimate of $0.68 by $0.15. The specialty pharmaceutical company earned $46.60 million during the quarter, compared to analyst estimates of $48.88 million. Eagle Pharmaceuticals had a net margin of 15.32% and a return on equity of 21.89%. The business's quarterly revenue was down 39.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.42 earnings per share. View Eagle Pharmaceuticals' Earnings History.

What price target have analysts set for EGRX?

4 brokerages have issued 1-year price targets for Eagle Pharmaceuticals' stock. Their forecasts range from $54.00 to $81.00. On average, they anticipate Eagle Pharmaceuticals' share price to reach $71.25 in the next twelve months. View Analyst Ratings for Eagle Pharmaceuticals.

What are Wall Street analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (6/13/2018)
  • 2. Mizuho analysts commented, "We don’t yet have this product in our model, and don’t expect it to be a meaningful revenue generator because Treanda powder currently has minimal market share. Big bag" may provide insurance if Eagle fails to bar Treanda generics from the market via its Orphan Drug litigation, in our view. The Fulvestrant clinical trial is fully enrolled, and data are expected in the fall. Additionally, the FDA accepted Eagle’s Vasostrict ANDA, which Endo indicated would be subject to the full litigation pathway. We have no estimates for the Ryanodex program for nerve agent exposure and note that Eagle did not provide an update on its drug- induced hyperthermia program, which we believe could get dropped. We summarize 1Q:18 performance below and reiterate our Underperform rating." (5/10/2018)

Who are some of Eagle Pharmaceuticals' key competitors?

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:
  • Mr. Scott L. Tarriff, Chief Exec. Officer and Director (Age 58)
  • Mr. David M. Pernock, Pres and Chief Commercial Officer (Age 65)
  • Dr. Adrian Hepner M.D., Ph.D., Chief Medical Officer and Exec. VP (Age 57)
  • Mr. Pete A. Meyers, Chief Financial Officer and Principal Accounting Officer (Age 48)
  • Mr. Daniel O'Connor, Exec. VP of Biologics and Corp. Devel. (Age 38)

Has Eagle Pharmaceuticals been receiving favorable news coverage?

Media stories about EGRX stock have trended somewhat positive on Friday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of 0.11 on Accern's scale. They also gave media coverage about the specialty pharmaceutical company an impact score of 48.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.42%), Park West Asset Management LLC (7.08%), Victory Capital Management Inc. (6.87%), Iridian Asset Management LLC CT (5.89%), LSV Asset Management (5.79%) and First Eagle Investment Management LLC (3.38%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., First Eagle Investment Management LLC, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Old Mutual Global Investors UK Ltd., GSA Capital Partners LLP, Victory Capital Management Inc., Royal Bank of Canada and Iridian Asset Management LLC CT. View Insider Buying and Selling for Eagle Pharmaceuticals.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management, Guggenheim Capital LLC, UBS Group AG, Schwab Charles Investment Management Inc., BlackRock Inc., Park West Asset Management LLC, Virginia Retirement Systems ET AL and Federated Investors Inc. PA. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $76.01.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $1.10 billion and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]


MarketBeat Community Rating for Eagle Pharmaceuticals (EGRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.